Intellia Therapeutics, Inc | NTLA

Daily Technical Analysis of Intellia Therapeutics, Inc

Intellia Therapeutics had a nice pop today and is currently up 9.69% -- which is pretty good. Investors have a more positive outlook for the company and future revenue. It looks like NTLA may be interacting with a slightly angled support line. This area could represent a pivot point that it moves up from. It's definitely important to take into account the directional momentum, so let's be honest Intellia Therapeutics has looked terrible. Buyers haven't seemed that interested, sellers keep dumping, there's been a lot of better places to put your money. It doesn't make me feel that optimistic about getting a solid bounce off of a line like this. If you do get one, I'd move your stop losses up with it. Owners of the Biotechnology company have lost -70.92 percent over the last year. If the price moves back up it'll probably hit pockets of sellers who want to break even and exit the position.

If the price bounces off of the support and moves up it'll probably head up to the $9 level, at which point it may hit some selling pressure. There aren't very obvious support levels beneath this point. So put those stop losses on, this thing has room to fall if buyers don't come in at this level.

Analyst Ratings for Intellia Therapeutics By Price Target And Rating

The analysts are pretty neutral on Intellia Therapeutics right now, so not much useful information here. The current Analysts Sentiment Score is -1.23. Most companies range between (-200 to 200).

Here's a break down of the latest rating changes. The Goldman Sachs Group downgraded from Buy to Neutral on 2024-02-23 and they lowered their price target by -76.47% to $32.00 from a previous target of $136.00. On 2024-02-23 Canaccord Genuity Group increased their price target by 1.39% to $73.00. On 2024-02-15 there was confirmation of the previous rating by Wedbush which was Neutral and provided a price target of $29.00. On 2024-02-15 Wolfe Research started covering Intellia Therapeutics with a rating of Peer Perform. Oppenheimer announced a lowering of their price target to $70.00 from $80.00 on 2023-11-13. Morgan Stanley announced a lowering of their price target to $85.00 from $90.00 on 2023-11-13. Raymond James announced a lowering of their price target to $57.00 from $78.00 on 2023-11-10. BMO Capital Markets provided a price target decease of -3.13% to $62.00 from $64.00 on 2023-11-10. Royal Bank of Canada announced a lowering of their price target to $70.00 from $80.00 on 2023-11-10. Cantor Fitzgerald announced that they are reiterating a rating of Overweight on 2023-09-13 and they set their price target at $65.00.

Earnings Per Share (EPS) Estimates By Year and Quarter

Short interest for Intellia Therapeutics

We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.

Social Sentiment for Intellia Therapeutics

Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.